Systematic review of autosomal recessive ataxias and proposal for a classification

Marie Beaudin, Christopher J. Klein, Guy A. Rouleau and Nicolas Dupré

Abstract

Background: The classification of autosomal recessive ataxias represents a significant challenge because of high genetic heterogeneity and complex phenotypes. We conducted a comprehensive systematic review of the literature to examine all recessive ataxias in order to propose a new classification and properly circumscribe this field as new technologies are emerging for comprehensive targeted gene testing.

Methods: We searched Pubmed and Embase to identify original articles on recessive forms of ataxia in humans for which a causative gene had been identified. Reference lists and public databases, including OMIM and GeneReviews, were also reviewed. We evaluated the clinical descriptions to determine if ataxia was a core feature of the phenotype and assessed the available evidence on the genotype-phenotype association. Included disorders were classified as primary recessive ataxias, as other complex movement or multisystem disorders with prominent ataxia, or as disorders that may occasionally present with ataxia.

Results: After removal of duplicates, 2354 references were reviewed and assessed for inclusion. A total of 130 articles were completely reviewed and included in this qualitative analysis. The proposed new list of autosomal recessive ataxias includes 45 gene-defined disorders for which ataxia is a core presenting feature. We propose a clinical algorithm based on the associated symptoms.

Conclusion: We present a new classification for autosomal recessive ataxias that brings awareness to their complex phenotypes while providing a unified categorization of this group of disorders. This review should assist in the development of a consensus nomenclature useful in both clinical and research applications.

Keywords: Cerebellar ataxia, Spinocerebellar degenerations, Recessive, Genetics, Classification
abnormalities, cognitive involvement, seizures, retinopathy, hypogonadism, and many others. This explains the high variability in the list of included disorders in recent literature reviews on recessive ataxias [7, 8].

Nevertheless, the advent of next generation sequencing techniques requires to properly determine which disorders belong to each disease category in order to design thoughtful targeted panels and facilitate the interpretation of whole exome and whole genome sequencing data. Indeed, targeted panel sequencing is a highly effective method for the diagnosis of neurological disorders, but it requires insightful categorization of disease phenotypes to respond to the specific needs of clinicians [9, 10]. Similarly, the interpretation of unknown variants in the analysis of whole exome or whole genome sequencing data poses a significant challenge for clinicians who must determine if the gene is associated with the suspected disease category and if the phenotype correlates with what has previously been described. As next generation sequencing techniques become increasingly available and the ability to detect DNA repeat expansion diseases improves [11], the proper classification of diseases will represent a useful tool in the interpretation of test results. Hence, this calls for a systematic effort to review recessive diseases in which ataxia is a prominent feature in order for experts in the field to collectively determine which disorders should be included in a recessive ataxia classification.

Therefore, the purpose of this article is to review the literature on recessive diseases presenting with ataxia in order to present a new classification. The goal is to bring together experts for the development of a much-needed consensus that fulfills research and clinical needs.

**Methods**

We conducted a systematic review to identify articles relevant to the classification of autosomal recessive ataxias. We searched PubMed and Embase from inception to September 2016 in order to identify original articles on disorders presenting with ataxia. The search strategy was large and targeted both recessive and sporadic ataxias, since recessive inheritance may appear sporadic in certain circumstances (full search strategy is provided in Additional file 1). We also reviewed reference lists of relevant articles and public databases including OMIM and GeneReviews to identify other relevant articles.

We reviewed the titles and abstracts of all identified references to select original articles on recessive forms of ataxia in humans for which a causative gene was identified. We evaluated the articles from a clinical perspective to determine if cerebellar ataxia was a prominent feature in the reported patients or rather a secondary finding in other movement or multisystem diseases. Diseases reporting only on cerebellar atrophy or cerebellar malformations without any clinical consequence were not included. For each listed disorder, we reviewed the evidence for a genotype-phenotype association using the US National Human Genome Research Institute guidelines [12]. Major considerations included the exclusion of previously described genes, the number of unrelated individuals described with similar genotype-phenotype correlations, the evidence of segregation with the disease, the absence of the variant in large control cohorts, and the presence of biochemical or animal-model functional validation. For the primary ataxias, we identified two relevant references from different research groups when possible. All relevant articles were fully reviewed to be included in this classification of recessive ataxias.
| Disorder     | Gene       | OMIM    | Additional clinical features and neuroimaging findings                                                                 | Relevant references |
|-------------|------------|---------|----------------------------------------------------------------------------------------------------------------------|---------------------|
| CTX         | CYP27A1    | 213700  | Dementia, paresis, tendon xanthomas, atherosclerosis, cataracts, elevated cholestanol level, childhood onset, variable cerebellar atrophy, cerebellar or cerebral leukodystrophy | [17, 18]            |
| AVED        | TTPA       | 277460  | Retinitis pigmentosa, head titubation, low serum vitamin E, teenage onset, spinal cord atrophy, absence of cerebellar atrophy | [19, 20]            |
| AT          | ATM        | 208900  | Telangiectasias, oculomotor apraxia, photosensitivity, immunodeficiency, predisposition for cancer, elevation of α-feto protein, infantile onset, cerebellar atrophy | [21, 22]            |
| FRDA        | FXN        | 229300  | Bilateral Babinski sign, square-wave jerks, scoliosis, hypertrophic cardiomyopathy, sensory involvement, teenage onset, spinal cord atrophy, absence of cerebellar atrophy | [5, 23]             |
| ATLD        | MRE11      | 604391  | Oculomotor apraxia, childhood onset, cerebellar atrophy | [24, 25]            |
| ARSACS      | SACS       | 270550  | Spastic paraparesis, retinal striation, pes cavus, infantile or childhood onset, anterior superior cerebellar atrophy, occasional T2-weighted linear hypointensities in pons | [26, 27]            |
| AOA1/EAOH   | APTX       | 208920  | Oculomotor apraxia, cognitive impairment, hypoalbuminemia, hypercholesterolemia, childhood onset, cerebellar atrophy | [28, 29]            |
| SCAN1       | TDP1       | 607250  | Peripheral axonal sensorimotor neuropathy, distal muscular atrophy, hypercholesterolemia, teenage onset, cerebellar atrophy | [30, 31]            |
| Cayman ataxia | ATCA1    | 601238  | Psychomotor retardation, hypotonia, strabism, neonatal onset, cerebellar hypoplasia | [32, 33]            |
| SANDO or MIRAS/SCAE | POLG1  | 607459  | In SANDO, sensory ataxia, ophtalmoparesis, myoclonus, ptosis, adult onset, variable cerebellar atrophy, cerebellar white matter lesions, stroke-like lesions. In MIRAS, cerebellar and sensitive ataxia, epilepsy, migraine, myoclonus, childhood or teenage onset, signal abnormalities in cerebellum and thalamus | [34, 35]            |
| AOA2        | SETX       | 606002  | Polyneuropathy, pyramidal signs, oculomotor apraxia, head tremor, chorea, dystonia, elevation of α-feto protein, teen age onset, cerebellar atrophy | [36, 37]            |
| CAMRQ1, DES | VLDLR      | 224050  | Non-progressive cerebellar ataxia, mental retardation, hypotonia, strabismus, occasional quadripedal gait, congenital onset, inferior cerebellar hypoplasia, cortical gyral simplification | [38, 39]            |
| IOSCA/MTDPS7 (Allelic to PEOA3) | C10orf2 | 271245  | Athetosis, hypotonia, optic atrophy, ophtalmoplegia, hearing loss, epilepsy, hypogonadism, liver involvement, infantile onset, moderate atrophy of brainstem and cerebellum with advancing disease | [40, 41]            |
| MSS         | SIL1       | 248800  | Cataracts, mental retardation, myopathy, short stature, childhood onset, cerebellar atrophy | [42, 43]            |
| DCMA/MGCA5  | DNAJC19    | 610198  | Dilated cardiomyopathy, non-progressive cerebellar ataxia, mental retardation, testicular dysgenesis, anemia, increased urinary 3-methylglutaconic acid, infantile onset | [44, 45]            |
| ARCA1       | SYNE1      | 610743  | Pure cerebellar ataxia, cognitive impairment, occasional pyramidal signs, late onset, cerebellar atrophy | [46, 47]            |
| ARCA2       | ADCK3 (CABC1) | 612016  | Exercise intolerance, epilepsy, myoclonus, cognitive impairment, childhood onset, cerebellar atrophy, occasional stroke-like cerebral lesions | [48, 49]            |
| SeSAME syndrome | KCNJ10  | 612780  | Epilepsy, sensorineural deafness, mental retardation, tubulopathy and electrolyte imbalance, infantile onset, absence of cerebellar atrophy | [50, 51]            |
| CAMRQ3      | C4B        | 613227  | Mild mental retardation, occasional quadripedal gait, congenital onset, cerebellar atrophy, white matter abnormalities | [52, 53]            |
| Salih ataxia/SCAR15 (1 family) | KIAA0226 | 615705  | Epilepsy, mental retardation, childhood onset, absence of cerebellar atrophy | [54, 55]            |
| PHARC       | ABHD12     | 612674  | Sensorimotor neuropathy, cataract, hearing loss, retinitis pigmentosa, teenage onset, variable cerebellar atrophy | [56, 57]            |
| SPAX4 (1 family) | MTPAP  | 613672  | Spastic paraparesis, optic atrophy, cognitive involvement, infantile onset | [58, 59]            |
| ARCA3       | ANO10      | 613728  | Cognitive impairment, downbeat nystagmus, teenage or adult onset, cerebellar atrophy | [60, 61]            |
| SCAR11 (1 family) | SYT14  | 614229  | Psychomotor retardation, late onset, cerebellar atrophy | [62]                |
| CAMRQ2      | WDR81      | 610185  | Occasional quadripedal gait, cognitive impairment, congenital onset, hypoplasia of cerebellum and corpus callosum | [63, 64]            |
| AOA3 (1 family) | PIK3R5  | 615217  | Oculomotor apraxia, sensorimotor involvement, teenage onset, cerebellar atrophy | [65]                |
Table 1 Proposed new list of autosomal recessive ataxias (Continued)

| SCAR13 | GRM1 | 614831 | Cognitive impairment, mild pyramidal signs, short stature, seizures, congenital onset, cerebellar atrophy [66, 67] |
| CAMRQ4 (1 family) | ATP8A2 | 615268 | Cognitive impairment, occasional quadrupedal gait, congenital onset, cerebellar and cerebral atrophy [68] |
| SCAR7 (Allelic to CLN2) | TPP1 | 609270 | Pyramidal signs, posterior column involvement, tremor, childhood onset, atrophy of the cerebellum and pons [69, 70] |
| Ataxia and hypogonadotropicism | RNF216 | 212840 | Hypogonadotropic hypogonadism, dementia, occasional chorea, childhood to young adult onset, cerebellar and cerebral atrophy [71, 72] |
| SCAR18 | GRID2 | 616204 | Tonic upgaze, psychomotor retardation, retinal dystrophy, infantile onset, cerebellar atrophy [73, 74] |
| SCAR16 | STUB1 | 615768 | Pyramidal signs, neuropathy, occasional hypogonadism, variable age at onset, cerebellar atrophy [75, 76] |
| SCAR12 | WWOX | 614322 | Tonic-clonic epilepsy, mental retardation, spasticity, neonatal to childhood onset, variable cerebellar or cerebral atrophy [77, 78] |
| ATLD2 (1 family) | PCNA | 615919 | Telangiectasias, sensorineural hearing loss, photosensitivity, cognitive impairment, short stature, childhood onset, cerebellar atrophy [79] |
| SCAR20 | SNX14 | 616354 | Mental retardation, sensorineural hearing loss, macrocephaly, dysmorphism, infantile onset, cerebellar atrophy [80, 81] |
| SCAR17 | CWF19L1 | 616127 | Mental retardation, congenital onset, cerebellar hypoplasia [82, 83] |
| ACPHD (1 family) | DNAJC3 | 616192 | Diabetes mellitus, UMN signs, demyelinating neuropathy, sensorineural hearing loss, childhood to adult onset, generalized supra- and infratentorial atrophy [84] |
| AKNS/SCAR19 (1 family) | SLC9A1 | 616291 | Sensorineural hearing loss, childhood onset, variable vermian atrophy [85] |
| AOA4 (Allelic to MCSZ) | PNKP | 616267 | Dystonia, oculomotor apraxia, polynuropathy, cognitive impairment, childhood onset, cerebellar atrophy [86, 87] |
| SCAR2 | PMPCA | 213200 | Non-progressive cerebellar ataxia, cognitive impairment, pyramidal signs, short stature, congenital or infantile onset, cerebellar atrophy [88, 89] |
| SCAR21 | SCYL1 | 616719 | Liver failure, peripheral neuropathy, mild cognitive impairment, childhood onset, cerebellar vermis atrophy, thinning of optic nerve [90] |
| SCAR22 (1 family) | VWA3B | 616948 | Cognitive impairment, pyramidal signs, adult onset, cerebellar atrophy and thin corpus callosum [91] |
| SCAR23 (1 family) | TDP2 | 616949 | Tonic seizures, cognitive impairment, dysmorphism, childhood onset [92] |
| SCAR24 (1 family) | UBAS | 617133 | Cataracts, peripheral neuropathy, childhood onset, cerebellar atrophy [93] |
| Cerebellar ataxia with developmental delay (1 family) | THGSTL | - | Psychomotor retardation, pyramidal signs, childhood onset, vermis hypoplasia [94] |

ACPHD Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, AOA ataxia with oculomotor apraxia, ARCA autosomal recessive cerebellar ataxia, ARSACS autosomal recessive spastic ataxia of Charlevoix-Saguenay, AT ataxia-telangiectasia, ATLD ataxia-telangiectasia-like disorder, AVED ataxia with vitamin E deficiency, CA Cayman ataxia, CAMOS cerebellar ataxia mental retardation optic atrophy and skin abnormalities, CAMRQ cerebellar ataxia mental retardation with or without quadrupedal locomotion, DCM4 Dilated cardiomyopathy with ataxia, DES Desequilibrium syndrome, EAOH early-onset ataxia with oculo-motor apraxia and hypoalbuminemia, FRDA Friedreich ataxia, IOSCA infantile onset spinocerebellar ataxia, LIKNS Lichtenstein-Knorr syndrome, MGCAS 3-methylglutaconic aciduria type 5, MIRR5 mitochondrial recessive ataxia syndrome, MCSZ Microcephaly seizures developmental delay, MISS Marinesco-Sjogren syndrome, MTDP57 mitochondrial DNA depletion syndrome 7, PEG43 progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, PHARC polyneuropathy hearing loss ataxia retinitis pigmentosa and cataract, SANDO sensory ataxic neuropathy with dysarthria and ophthalmoplegia, SCAE spinocerebellar ataxia with epilepsy, SCAN1 spinocerebellar ataxia with axonal neuropathy 1, SCAR Spinocerebellar ataxia, autosomal recessive, SCASEE Seizures sensorineural deafness ataxia mental retardation and electrolyte imbalance, SPAX spastic ataxia, UMN upper motor neuron

Identified disorders were classified in three categories: the first included the primary autosomal recessive ataxias, the second included other movement or multi-system recessive diseases that have prominent ataxia, and the final group was composed of recessive disorders that may occasionally present with ataxia, but where ataxia is a secondary feature.

We also developed a clinical algorithm for the primary recessive ataxias based on the most frequent phenotype and cardinal symptoms associated with each disorder. The objective of this algorithm is to rapidly summarize the main discriminatory features between different ataxias to serve in a clinical setting, but also as a pedagogical and research tool.

Results

3750 references were identified through the literature search in Pubmed and Embase, and 49 additional references were identified through reference lists or public databases. After removal of duplicates, 2354 references
| Disorder                                           | Gene      | OMIM    | Clinical features and imaging findings                                                                 | Comment            | References |
|---------------------------------------------------|-----------|---------|---------------------------------------------------------------------------------------------------------|--------------------|------------|
| Abetalipoproteinemia                              | MTTP      | 200100  | Fat malabsorption symptoms, hypcholesterolemia, hypotriglyceridemia, acanthocytosis, Friedreich-ataxia, neonatal onset, absence of cerebellar atrophy | Multisystem        | [95]       |
| Nieman Pick type C                                | NPC1      | 257220  | Vertical supranuclear ophtalmoplegia, ataxia, splenomegaly, childhood to adult onset, variable cerebellar or cerebral atrophy | Multisystem        | [96, 97]   |
| Nieman Pick type C                                | NPC2      | 607625  |                                                                                                        |                    |            |
| Refsum disease                                     | PAHX      | 266500  | Retinitis pigmentosa, polyneuropathy, ataxia, increased CSF protein, anosmia, deafness, ichthyosis, teenage onset, elevated serum phytanic acid, absence of cerebellar atrophy | Multisystem        | [98, 99]   |
| Late-onset GM2 gangliosidosis (Tay-Sachs, Sandhoff) | HEXA      | 272800  | Ataxia, dysarthria, intellectual impairment, extrapyramidal signs, adult onset, cerebellar atrophy       | Lysosomal storage disease | [100–102] |
| Late-onset GM2 gangliosidosis (Tay-Sachs, Sandhoff) | HEXB      | 268800  |                                                                                                        |                    |            |
| SPARCA1                                            | SPTBN2    | 615386  | Ataxia, cognitive impairment, eye-movement abnormalities, early childhood onset, cerebellar atrophy        | Allelic to SCAS     | [9, 103]   |
| SPAX5                                             | AFG3L2    | 614487  | Ataxia, spasticity, oculomotor apraxia, myoclonic epilepsy, neuropathy, dystonia, optic atrophy, childhood onset, cerebellar atrophy | Allelic to SCA28    | [104, 105] |
| Boucher-Neuhauser/Gordon Holmes syndrome           | PNPLA6    | 215470  | Ataxia, hypogonadotropic hypogonadism, chorioretinal dystrophy or brisk reflexes, childhood onset, atrophy of cerebellum and pons | Allelic to HSP39    | [106, 107] |
| Gillespie syndrome                                | ITPR1     | 206700  | Non-progressive cerebellar ataxia, iris hypoplasia, cognitive impairment, neonatal onset, progressive cerebellar atrophy | Allelic to SCA1S/29 | [108]      |
| SPAX2/SPG58                                       | KIF1C     | 611302  | Spastic paraparesis, cerebellar ataxia, childhood or teenage onset, white matter changes in the internal capsule | Spasticity predominant | [109, 110] |
| SPG7                                              | SPG7      | 607259  | Spasticity, pyramidal signs, cerebellar signs, optic neuropathy, ptosis, teenage or adult onset, cerebellar atrophy | HSP                | [111, 112] |
| SPG5                                              | CYP7B1    | 270800  | Spasticity, cerebellar and sensory ataxia, childhood or teenage onset, white matter lesions               | HSP                | [113, 114] |
| SPG11                                             | KIAA1840  | 604360  | Spasticity, ataxia, cognitive impairment, sensorimotor neuropathy, childhood or teenage onset, thin corpus callosum, signal abnormalities in cervical cord | HSP                | [115, 116] |
| SPG46                                             | GBA2      | 614409  | Cerebellar ataxia, spastic dysarthria, mild cognitive impairment, hearing loss, cataracts, childhood onset, cerebellar and cerebral atrophy, thin corpus callosum | HSP                | [117, 118] |
| Congenital disorders of glycosylation type 1A      | PMM2      | 212065  | Psychomotor retardation, axial hypotonia, abnormal eye movements, peripheral neuropathy, congenital onset, cerebellar hypoplasia | Neonatal onset, complex syndrome | [119, 120] |
| LBL                                               | DARS2     | 611105  | Cerebellar ataxia, tremor, spasticity, dorsal column dysfunction, axonal neuropathy, childhood onset, cerebellar and cerebral atrophy, thin corpus callosum | Leukoencephalopathy | [121, 122] |
| Mitochondrial complex IV deficiency                | COX20     | 220110  | Cerebellar ataxia, dystonia, sensory axonal neuropathy, variable childhood or teenage onset, cerebellar atrophy | Dystonia predominant | [123]      |
| Aceruloplasminemia                                 | CP        | 604290  | Diabetes, dementia, movement disorder, cerebellar ataxia, retinal degeneration, late onset, decreased signal intensity in thalamus, basal ganglia and dentate nucleus | Metabolic disorder  | [124]      |
| Neurodegeneration with brain iron accumulation 2A and 2B | PLA2G6  | 256600  | Cerebellar ataxia, psychomotor retardation, psychiatric features, ataxia, axonal sensorimotor neuropathy, infantile or teenage onset, cerebellar atrophy and variable iron accumulation in globus pallidus | Neurodegeneration with brain iron accumulation | [125, 126] |
| Poretti-Bochus syndrome                            | LAMA1     | 615960  | Nonprogressive ataxia, oculomotor ataxia, psychomotor retardation, early childhood onset, cerebellar dysfunction and infantile or childhood onset, dystrochiasis with cysts | Dystrochiasis       | [127]      |
| Posterior column ataxia with retinitis pigmentosa  | FLVCR1    | 609033  | Posterior column degeneration and retinitis pigmentosa, childhood onset, signal abnormalities in cervical spinal cord | Sensory ataxia     | [128, 129] |

HSP hereditary spastic paraplegia, LBSL leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation, SPARCA1 spectrin-associated autosomal recessive cerebellar ataxia type 1, SPAX spastic ataxia, SPG spastic paraplegia
were reviewed on the basis of title and abstract. Finally, 130 articles were selected on the basis of the aforementioned criteria and completely reviewed to be included in this qualitative analysis (Fig. 1).

The proposed new list of autosomal recessive ataxias is presented in Table 1 in chronological order of gene discovery. The disorders included in this list were evaluated as having a relatively predominant cerebellar involvement compared to the involvement of other neurologic and non-neurologic systems. Table 2 presents the other complex motor or multisystem disorders that have prominent ataxia. Finally, Table 3 presents disorders that may occasionally present with ataxia, but where ataxia is a secondary feature. Certain decisions were made in the elaboration of this classification. Notably, abetalipoproteinemia (ABL) and Refsum disease were not included in the list of primary recessive ataxias, but rather in the list of complex disorders that have prominent ataxia. Indeed, despite their important Friedreich-like neurological picture, these disorders are primary lipid metabolism disorders with multisystem involvement. Moreover, ataxic disorders that are allelic to other movement disorders, especially spinocerebellar ataxias and hereditary spastic paraplegias, were assigned to the second category to avoid any confusion with the primary recessive ataxias. The MARS2-linked autosomal recessive ataxia with leukencephalopathy (ARSAL/SPAX3) was not included because the genetic evidence was deemed insufficient [13]. Finally, some disorders described only in single families were included, despite this being a factor for weaker genetic evidence, if other major considerations were met; this was indicated in the list.

The primary recessive ataxias were also organized in a clinical algorithm (Fig. 2) according to the presence of key clinical clues, which include the presence of sensorimotor involvement, cognitive impairment, spasticity, and oculomotor abnormalities.

Other disorders have been reported with ataxia, but the authors evaluated that these disorders did not need to be included in the differential diagnosis of recessive ataxias. However, clinicians may bear in mind that the following may have ataxia as an associated feature: Lafora disease (EPM2A, EPM2B), megalencephalic leukoencephalopathy with subcortical cysts (MLC1), COL18A1-linked ataxia epilepsy cognitive problems and visual problems, Perrault syndrome (HSD17B4), Zellweger-spectrum disorders (PEX2), Wolfram syndrome (WFS1), Canavan disease (ASPA), metachromatic leukodystrophy (ARSA), Galloway-Mowat syndrome (WDR73), and GLUT-1 deficiency (SCL2A1).

**Discussion**

We present a new classification for the autosomal recessive ataxias. This classification should allow for better...
categorization of recessive disorders presenting with ataxia with a clear separation between the primary recessive ataxias and disorders that may present with ataxia as an associated feature but belong to other disease categories. We also provided a clinical algorithm as a tool for diagnostic, learning, and research purposes. This comprehensive classification will allow for improved genetic diagnosis by targeted next generation sequencing applications as the ability to detect DNA repeat expansion diseases is quickly becoming a reality with prospects of treatment in the future [11, 14, 15].

As compared to previously published reports on this subject [7, 8], we systematically reviewed the literature to evaluate the available evidence on the disease-associated genes in order to include all disorders presenting with a predominant cerebellar ataxia phenotype. The systematic review methodology with a structured data search and comprehensive evaluation of all references allowed for a complete evaluation of the literature regarding disorders presenting with ataxia to ensure that all potentially relevant disorders were included in this classification. Nevertheless, some methodological elements were not applicable to the task at hand. For example, two references were selected for each primary recessive ataxia, and articles that provided evidence for a separate genetic basis with a clinical corollary of ataxia were preferred. Therefore, some articles that provided only detailed clinical description were not included. Moreover, inclusion criteria were clearly defined but there remained a place for interpretation to determine if cerebellar ataxia was a core feature of the phenotype and if the genotype-phenotype association was convincing. Thus, the classification of individual disorders between the three groups, i.e. as a recessive ataxia, a complex disorder with predominant ataxia or a disorder where ataxia is a secondary feature, remains a subjective appreciation and is open for discussion by a dedicated task force in order to reach a consensus. Finally, the search

Fig. 2 Clinical algorithm of autosomal recessive ataxias

If negative, consider testing for polyglutamine expansion SCAs, FXTAS or other disorders listed in Tables 2 and 3
strategy was designed to be as sensible as possible, but ataxia is a frequent symptom in neurology, and it is possible that other ataxia-associated disorders could be considered for inclusion.

Important challenges remain to be addressed. First, the nosology of recessive ataxias is still highly confusing. Contrary to the dominantly inherited spinocerebellar ataxias, no universal acronym was adopted in the field of recessive ataxias, such that disorders were named based on the author who first described them, on regions of high prevalence, or according to clinical presentation. In the last few years, the term spinocerebellar ataxia, autosomal recessive (SCAR) was used to designate novel recessive ataxias, but this nomenclature did not include the previously described and most frequent ataxias. Moreover, as SCAR assignment was based on locus discovery, some of the included SCARs do not correspond to an identified gene. The term SPAX has also been used to designate ataxias with a strong spasticity component, irrespectively of their mode of inheritance. Recently, the International Parkinson and Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders recommended a nomenclature with a gene suffix in order to overcome the shortcomings of the numbered locus system, which include erroneously assigned loci, the mingling of causative and risk factor genes, unconfirmed causative associations, and inconsistent phenotypic correlations [16]. These concerns are justified, although numbered naming systems present definite advantages for ease of use and proper delineation of the field. The nomenclature of recessive ataxias should be discussed by a dedicated task force of international experts in order to develop a naming system that reflects the complexity of the recessive ataxia phenotypes while allowing convenient clinical use.

Finally, large phenotypic variability exists between patients from different families and even from a single family with the same mutated gene, depending on the type of mutation and on its location in the gene. Other factors that affect age at onset and clinical course probably include the presence of modifier genes and environmental exposures. Hence, one could argue that the paradigm of one gene-one disease presented here does not reflect all the phenotypic variability observed, and could as well be replaced by the concept of one patient-one disease as we identify new genetic and environmental prognostic features that characterise more precisely the age at onset, evolution, and response to treatment. Such developments are likely to modify our understanding of genetic disorders and of their classification.

Conclusion
We present herein a classification of the autosomal recessive ataxias based on a systematic review of the literature. This work should serve as a framework for scientific discussion in order to bring together experts for the establishment of a much-needed consensus in this field.

Appendix 1: Search strategy for MEDLINE/PubMed.

Acknowledgements
Not applicable.

Funding
MB is supported by the Canadian Institutes of Health Research. This study was conducted independently of the funding body.

Availability of data and materials
The dataset of records screened for publication generated during this study can be obtained using the search strategy provided in the additional file.

Authors’ contributions
MB designed the search strategy, conducted the systematic review, and drafted the manuscript. CJK, GAR, and ND provided essential intellectual input and revised the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Faculty of Medicine, Université Laval, Quebec city, QC G1V 0A6, Canada.
2Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
3Department of Neurology and Neurosurgery, McGill University, Montreal, QC H3A 1A4, Canada.
4Department of Neurological Sciences, CHU de Quebec - Université Laval, 1401 18th street, Quebec City, QC G1J 1Z4, Canada.

Received: 22 November 2016 Accepted: 17 February 2017
Published online: 23 February 2017

References
1. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore MD. https://omim.org/. Accessed 15 Sept 2016.
2. Greenfield JG. The Spinocerebellar Degenerations. Oxford: Blackwell; 1954.
3. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151–5.
4. Orr HT, Chung MY, Banfi S, Kwiatkowski Jr TJ, Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221–6.
5. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–7.
6. Bird TD. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, McFerrin FC, Smith RJH, Stephens K, editors. Hereditary Ataxia Overview. Seattle: GeneReviews (R); 1993.
7. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med. 2012;366:636–46.
8. Vermeer S, van de Warrenburg BP, Willemsen MA, Cluitmans M, Scheffer H, Kremer BP, Knoers NV. Autosomal recessive cerebellar ataxias: the current state of affairs. J Med Genet. 2011;48:651–9.
9. Nemeth AH, Kwasniiewska AC, Lise S, Panolin Schnekenberg R, Becker EB, Bera KD, Shank ME, Gregory L, Buck D, Zameel Cader M, et al. Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain. 2013;136:1106–18.

11. Rhoads A, Au KF. PacBio Sequencing and Its Applications. Genomics Proteomics Bioinformatics. 2015;13:278–89.

12. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–76.

13. Bayat V, Thiffault J, Jawad M, Tetreault M, Donti T, Saasaman F, Bernard G, Demers-Lamarche J, Dicaire MJ, Mathieu I, et al. Mutations in the mitochondrial methionine-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol. 2012;10,e1001288.

14. Cinessi A, Aeschbach L, Yang B, Dion V. Contracting CAG/CTG repeats using a high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am J Hum Genet. 1996;59:839–47.

15. Loomis EW, Eid JS, Peluso P, Yin J, Hickey L, Rank D, McCalmon S, Hagerman RJ, Tassone F, Hagerman PJ. Sequencing the unsequencetable: expanded CGG-repeat alleles of the fragile X gene. Genome Res. 2013;23:121–8.

16. Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, van den Maagdenberg AMJ, Loonen GS, Faber PM, et al. Friedreich-like ataxia with retinitis pigmentosa caused by homozygous mutations in the alpha-tocopherol transfer protein. Nat Genet. 1995;9:141–6.

17. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266:7779–83.

18. Demers-Lamarche J, Dicaire MJ, Mathieu J, et al. Mutations in the mitochondrial protein p97-UFD1N cause autosomal recessive cerebellar ataxia-ocular apraxia 2. N Engl J Med. 2004;350:267–72.

19. Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M, Sokol R, Arai H, Inoue K, Mandel JL, Koenig M. Ataxia with isolated vitamin E deficiency is caused by mutations in the very low-density lipoprotein receptor gene (VLDLR) in an Iranian family with dyslipidemia syndrome. Eur J Hum Genet. 2005;13:275–9.}

20. Yokota T, Shiokii T, Gotoda T, Arita M, Arai H, Ohga T, Kanda T, Suzuki J, Imai T, Matsumoto H, et al. Friedreich-like ataxia with retinitis pigmentosa caused by a high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am J Hum Genet. 1996;59:839–46.

21. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335:1169–75.

22. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, Taylor AM. The DNA double-strand break repair protein hMRE11: genomic structure and a high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am J Hum Genet. 1996;59:839–46.

23. Pitts SA, Kullar HS, Stankovic T, Stewart GS, Last J, Bedenham T, Armstrong SJ, Piane M, Chessa L, Taylor AM, Byrd PJ. hMR1E11: genomic structure and a null mutation identified in a transcript protected from nonsense-mediated mRNA decay. Hum Mol Genet. 2001;10:155–62.

24. Engh JC, Berube P, Mercier J, Dore C, Legaye P, Gibson T, Monorchon P, Costa M, Barros J, Nanayagawa T, et al. The gene mutated in ataxia-oculomotor apraxia 1 encodes the new HIT/CrAL-TRIO domain protein. J Biol Chem. 2001;276:14655–62.

25. Criscuolo C, Barfl S, Orito M, Gasparini P, Monticelli A, Scavano V, Santorelli FM, Perretti A, Santoro L, De Michele G, Gilla F, A Novel mutation in SACS gene in a family from southern Italy. Neurology. 2004;62:100–2.

26. Moreira MC, Barbott T, Tachi N, Konuka N, Uchida E, Gibson T, Santorelli FM, Perretti A, Santoro L, De Michele G, Gilla F, A Novel mutation in SACS gene in a family from southern Italy. Neurology. 2004;62:100–2.

27. Moreira MC, Barbott T, Tachi N, Konuka N, Uchida E, Gibson T, Santorelli FM, Perretti A, Santoro L, De Michele G, Gilla F, A Novel mutation in SACS gene in a family from southern Italy. Neurology. 2004;62:100–2.

28. Moreira MC, Barbott T, Tachi N, Konuka N, Uchida E, Gibson T, Santorelli FM, Perretti A, Santoro L, De Michele G, Gilla F, A Novel mutation in SACS gene in a family from southern Italy. Neurology. 2004;62:100–2.

29. Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, Koike R, Hiroi T, Yuasa T, Awaya Y, et al. Early-onset ataxia with oculomotor apraxia and hypoalbinemia is caused by mutations in a new HIT superfamily gene. Nat Genet. 2001;29:184–8.

30. Takashima H, Boerkoel CF, John J, Safi GM, Salih MA, Armstrong D, Mao Y, Quicho FO, Roa BB, Naikagawa M, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet. 2002;32:267–72.

31. El-Khamisy SF, Safi GM, Weinfield M, Johannson F, Helleday T, Luptski JR, Caldecott KW. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature. 2005;434:108–13.

32. Bomar JM, Benke PJ, Slattery EL, Puttagunta R, Taylor LP, Seong E, Nystuen A, Chen W, Albin RL, Patel PD, et al. Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cajman ataxia and ataxia/dystonia in the Jittery mouse. Nat Genet. 2005;37:264–9.

33. Manzoor H, Brüggemann N, Hinrichs F, Hussain HMJ, Wajid B, Bäumer T, Munchau A, Naz S, Lohmann K. Exome sequencing reveals homozygous mutations in SACS, ATCAY, and MCOLN1 in three Pakistani families with complex dystonia. Mov Disord. 2016;31:5535.
52. Vohra RS, Nandy S, Joshi S, Hawryluk LG, Lee CH, et al. The role of FACL1 in the pathogenesis of myoclonic-epileptic encephalopathy. Am J Hum Genet. 2016;99:454–61.

53. Kumar A, Mehtani P, Kaur J, et al. Novel missense mutation in the GPR65 gene in a patient with Leigh syndrome and encephalopathy. Neuromuscul Disord. 2015;25:153–6.

54. Diller X, De Bie P, Jordaens L, et al. Novel mutations of STXBP1 in two families with late-onset autosomal recessive hearing loss. Eur J Hum Genet. 2016;24:628–34.

55. Kryscio RL, Elsesser E, coli B, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.

56. De plotski T, Huse C, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.

57. Vermeersch P, van den Berghe H, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.

58. Beaudin M, Huttner WB, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.

59. Santenari M, Del Zotto F, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.

60. Beaudin M, Huttner WB, et al. Mutations in the CLN2 gene are associated with late-onset ataxia and Friedreich's ataxia. Hum Genet. 2016;135:515–24.
85. Guissart C, Li X, Leheup B, Drouot N, Montaut-Verient B, Raffo E, Jonveaux P, Roux AF, Claustres M, Fliegel L, Koenig M. Mutation of SLC9A1, encoding the major Na(+)/H(+) exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome. Hum Mol Genet. 2015;24:643–70.

86. Bras J, Alonso I, Barbot C, Costa MM, Darwent L, Orme T, Sequeiros J, Hardy J, Coutinho P, Guerreiro R. Mutations in PNP cause recessive ataxia with oculomotor apraxia type 4. Am J Hum Genet. 2015;96:647–94.

87. Pauzac M, Malmgren H, Taylor M, Reynolds JJ, Svenningsson P, Press R, Nordgren A. Expanding the ataxia with oculomotor apraxia type 4 phenotype. Neurol Genet. 2016;2:e49.

88. Jobling RK, Assoum M, Gakh O, Blaser S, Raiman JA, Mignot C, Roze E, Durr O, Jakobs C, Besley GT, Wraith JE, Wanders RJ. Refsum disease is caused by a new form of autosomal recessive developmental delay. PLoS Genet. 2012;8, e1003074.

89. Gomez-Hernandez F, Schuurs-Hoeijmakers JH, McCormack M, Grealy MT, Rutten S, Romanos-Granados R, Couninck CH, Chalopin E, Conroy J, Ennis S, et al. NDP2 protects transcription from abortive topoisomerases and is required for normal neural function. Nat Genet. 2014;46:516–21.

90. Duan R, Shi Y, Yu L, Zhang G, Li J, Lin Y, Guo J, Wang J, Shen L, Jiang H, et al. UBAS Mutations Cause a New Form of Autosomal Recessive Cerebellar Ataxia. PLoS ONE. 2016;11, e0149039.

91. Edvardson S, Elbaz-Alon Y, Jalis C, Matlock A, Patel K, Labbe K, Shaag A, Jackman JE, Elpeleg O. A mutation in the THG1 gene in a family with cerebellar ataxia and developmental delay. Neurogenetics. 2016.

92. Sharp D, Blinderman L, Combs KA, Kiemzle B, Ricci B, Wager-Smith K, Gil CM, Turk CW, Bourou ME, Rader DJ, et al. Cloning and gene defects in SPTBN2 implicate beta-III spectrin in both cognitive and motor disorders. PLoS Genet. 2012;8, e1003074.

93. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot JC, Nguyen TM, Nardocci N, Zorzi G, et al. Neurodegeneration associated with Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain. 2014;137:69–77.

94. Koh K, Kobayashi F, Miyva M, Shindo K, Izatoz E, Ishihara H, Tsuji S, Takayama Y. Novel mutations in the PNPLA6 gene in Boucher-Neuhauser syndrome. J Hum Genet. 2015;60:217–20.

95. Gerber S, Alzayady KJ, Burglen L, Bremond-Gignac D, Marchesin V, Roche O, Rivo F, Furutol B, Calmon R, Durr A, et al. Recessive and Dominant De Novo IPTR1 Mutations Cause Gillespie Syndrome. Am J Hum Genet. 2016;98:8971–80.

96. Dor T, Cinnamin Y, Raymond L, Shaag A, Bouslam N, Bouhouche A, Gaussen M, Meyer V, Durr A, Brice A, et al. KIF1C mutations in two families with hereditary spastic paraparesis and cerebellar dysfunction. J Med Genet. 2014;51:137–42.

97. Caballero Oteyza A, Battalougi E, Ock C, Lindig T, Reichbauer J, Rebelo AP, Gonzalez MA, Zorzu Y, Ozes B, Timmann D, et al. Motor protein mutations cause a new form of hereditary spastic paraplegia. Neurology. 2014;82:2007–16.

98. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Coutinho P, Guerreiro R. Mutations in PNKP cause recessive ataxia-neuropathy syndrome. Ann Neurol. 2010;68:S68.

99. Jansen GA, Ofman R, Ferdinandusse S, Ijlst L, Muijsers AO, Skjeldal OH, Stokke HC, Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain. 2014;137:69–77.

100. Jobling RK, Assoum M, Gakh O, Blaser S, Raiman JA, Mignot C, Roze E, Durr O, Jakobs C, Besley GT, Wraith JE, Wanders RJ. Refsum disease is caused by a new form of autosomal recessive developmental delay. PLoS Genet. 2012;8, e1003074.
126. Salih MA, Mundwiller E, Khan AO, AI-Drees A, Elmalik SA, Hassan HH, Al-Owain M, Alkhalihi HW, Katona I, Kabinaj MM, et al. New findings in a global approach to dissect the whole phenotype of PL2G6 gene mutations. PLoS ONE. 2013;8:e6831.

127. Aldinger KA, Mosca SJ, Tetteault M, Dempsey JC, Ishak GE, Hartley T, Phelps IG, Lamont RE, O'Day DR, Basel D, et al. Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophy. Am J Hum Genet. 2014;95:272–34.

128. Rajadhyaksha AM, Elemento O, Puffenberger EG, Schierberl KC, Xiang JZ, Salih MA, Mundwiller E, Khan AO, Al-Drees A, Elmalik SA, Hassan HH, Al-Beaudin et al. Cerebellum & Ataxias

130. Faruq M, Narang A, Kumari R, Pandey R, Garg A, Behari M, Dash D, Klockars T, Savukoski M, Isosomppi J, Peltonen L. Positional cloning of the CLN5 gene defective in the Finnish variant of the LINCL. Mol Genet Metab. 1995;61:242–8.

131. Kleta R, Romeo E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, Dave MH, Cantagrel V, Silhavy JL, Bielas SL, Swistun D, Marsh SE, Bertrand JY, Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill RS, Al-Nouri D, Al-Rumayyan A, Aula N, Salomaki P, Timonen R, Verheijen F, Mancini G, Mansson JE, Aula P, Verheijen FW, Verbeek E, Aula N, Beerens CE, Havelaar AC, Joosse M, Steenweg ME, Jakobs C, Errami A, Van Dooren SJ, Adeva Bartolome MT, Bonneau D, Colin E, Oca F, Ferre M, Chevrollier A, Gueguen N, Desquiret-Dumas V, O'Conor GM, Barth M, Zantou X, et al. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain. 2014;137:e301.

132. Leegwater PA, Vermeulen G, Konst AA, Naidu S, Mulders J, Visser A, Aerssens P, Augoustides-Savvapoulou P, Baric I, Baumann M, Bonafe L, et al. Mutations in POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Neurology. 2004;63:1509–17.

133. Kleta R, Romee E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, Dave MH, Wagner CA, Camargo SR, Inoue S, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet. 2004;36:1008–13.

134. Corbett MA, Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DW, Price CM, Johnston PN, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat. 2010;31:380–90.

135. Bernard G, Chourey E, Purtiti ML, Tetteault M, Takahashii A, Carosso G, Clement I, Boespflug-Tanguy O, Rodriguez D, Delague V, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol II cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet. 2011;88:415–23.

136. Kleta R, Romee E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, Dave MH, Wagner CA, Camargo SR, Inoue S, et al. Mutations in SLC6A19, encoding BOAT1, cause Hartnup disorder. Nat Genet. 2004;36:999–1002.

137. Edgerton CR, Pineda M, Troncoso M, Uziel G, et al. The effect of genotype on the natural history of eIF2B-related leukoencephalopathies. Neurology. 2004;62:1509–17.

138. Fogli A, Schiffmann R, Bertini E, Ughetto S, Combes P, Eymard-Pierre E, Kaneski K, Souillet G, de Barros-Dias F, O'Conor GM, Barth M, Zantou X, et al. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain. 2014;137:e301.

139. Topcu M, Jobard F, Halliez S, Coskun T, Yalcinkayal C, Gerceker FO, Wanders RJ, Prud'homme JF, Lathrop M, Ozguc M, Fischer J. L-2-Hydroxyglutaric aciduria: Identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet. 2004;13:2802–11.

140. Steenweg ME, Jakobs C, Errami A, Van Dooren SJ, Adeva Bartolome MT, Aerssens P, Augoustides-Savvapoulou P, Baric I, Baumann M, Bonafe L, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat. 2010;31:380–90.

141. Corbett MA,Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DW, O'Sullivan JD, Robertson T, Bayly MA, et al. A mutation in the Golgi Qb- SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia. Am J Hum Genet. 2011;88:657–63.

142. Bernard G, Chourey E, Purtiti ML, Tetteault M, Takahashii A, Carosso G, Clement I, Boespflug-Tanguy O, Rodriguez D, Delague V, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol II cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet. 2011;88:415–23.

143. Bonneau D, Collin E, Oca F, Ferre M, Chevollier A, Gueguen N, Desquiret-Dumas V, N'Guen S, Barth M, Zantou X, et al. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain. 2014;137:e301.

144. Lee J, Jung SC, Hong YB, Yoo JH, Koo H, Lee JH, Hong HD, Kim SB, Chung KW, Choi BO. Reccessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1. Mol Med Rep. 2016;14:33–40.